Navigation Links
Diffusion Pharmaceuticals LLC Closes on $5.9 Million Financing
Date:1/29/2010

CHARLOTTESVILLE, Va., Jan. 29 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million. The financing was a combination of private equity and convertible notes to existing investors.  Proceeds will support the company's ongoing operations, including completion of a Phase I/II clinical trial in peripheral arterial disease (PAD) patients for its lead drug compound, trans sodium crocetinate (TSC).

"The successful financing in 2009 gives us the ability to complete our ongoing clinical trial in PAD and position the company for critical post proof-of-concept activities," said David G. Kalergis, Chief Executive Officer.

Since its founding, Diffusion Pharmaceuticals has raised a total of $21.7 million to date including $19.1 million in private funds, and $2.6 million in Department of Defense research and development contracts.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke, and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. A Phase I study in healthy subjects for Diffusion's lead molecule, trans sodium crocetinate (TSC), was successfully completed in 2007. The company is currently completing enrollment in a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. This study is designated NCT00725881 on the clinicaltrials.gov Website. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit www.diffusionpharma.com .

SOURCE Diffusion Pharmaceuticals LLC

RELATED LINKS
http://www.diffusionpharma.com

'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
3. Intercept Pharmaceuticals Raises $25 Million Series B Financing
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Amylin Pharmaceuticals to Webcast Year-End Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
8. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
9. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
10. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
11. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... China , 23. Februar 2017 Im ... , eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, ... der Errichtung einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten ... Continue Reading ... ...
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus Therapeutics ... discovery and development of innovative medicines targeting microRNAs, today ... 2016 financial results on Thursday, March 2, 2017 after ... conference call and webcast on March 2, 2017 at ... full year 2016 financial results and provide a general ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS Martin ... supporter of the event. , "We are pleased that KLS Martin is joining us ... ACPA President. "KLS Martin has a long track record of support of the American ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... provider for the National Institute for Health and Care Excellence (NICE) ... in the National Health Service (NHS) to search, order and purchase medical and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena ... 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... online directory that recognizes local physicians and dentists who have earned high ratings and ...
(Date:2/23/2017)... ... 2017 , ... ERT, a global data and technology company ... a leading clinical development service provider, has selected ERT’s Trial Oversight suite as ... part to an array of circumstances including the use of multiple data capture ...
Breaking Medicine News(10 mins):